Posted by Michael Wonder on 31 Oct 2023
PBS listing expanded to include treatment resistant high frequency episodic migraine
31 October 2023 - From 1 November 2023, Australians with treatment resistant high frequency episodic migraine will have access to fremanezumab (Ajovy) through the PBS.
This listing is expected to benefit around 6,100 patients per year. Without subsidy, patients may pay about $6,700 per year of treatment.
